NEW HAVEN, Conn., April 8, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will include Phase 1 results on ACH-3422, a NS5B nucleotide polymerase inhibitor, and detailed results from the Phase 2 proxy study evaluating ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir following 6- and 8-week treatment durations for treatment-naïve genotype 1 HCV. The congress is being held April 22 – 26 in Vienna, Austria. The abstracts can be accessed on the EASL website at https://ilc-congress.eu/ and posters will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.
Thursday, April 23, 2015
- LP06: Sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: A phase 2 "proxy" study ACH102-017. ePoster Presentation, April 23-25, 7:30 am - 8:00 pm CET, Hall B ePoster Area. Lead Author: Edward Gane.
- LP27: Gane, E., et al. ACH-3422, a novel nucleotide prodrug inhibitor of HCV NS5B polymerase. ePoster Presentation, April 23-25, 7:30 am - 8:00 pm CET, Hall B ePoster Area. Lead Author: Edward Gane.
- P0805: Achievement of SVR12 despite the presence of HCV variants resistant to first generation NS5A inhibitors in genotype-1 hepatitis C patients after 8-week therapy of ACH-3102 in combination with sofosbuvir. ePoster Presentation, April 23-25, 7:30 am - 8:00 pm CET, Hall B ePoster Area. Lead Author: Wengang Yang.
The hepatitis C virus is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 150 million people are infected with HCV worldwide including more than 5 million people in the United States. Three-fourths of the HCV patient population is undiagnosed; it is a silent epidemic and a major global health threat. Chronic hepatitis, if left untreated, can lead to permanent liver damage that can result in the development of liver cancer, liver failure or death.
About Achillion Pharmaceuticals
Achillion is seeking to apply its expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving patients' lives. The Company believes that its scientific excellence, integrated capabilities and experienced team position it to successfully achieve its goal of advancing new products along the entire continuum from the bench to the patient. Achillion's pipeline is currently focused on small molecule therapeutics for infectious disease and complement-related diseases. www.achillion.com
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Achillion may use words such as "expect," "anticipate," "project," "intend," "plan," "aim," "believe," "seek," " estimate," "can," "focus," "will," and "may" and similar expressions to identify such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things Achillion's ability to: demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; advance the preclinical and clinical development of its drug candidates, including ACH-3102, ACH-3422, and sovaprevir, under the timelines it projects in current and future clinical trials; obtain and maintain necessary regulatory approvals; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; establish commercial manufacturing arrangements; identify, enter into and maintain collaboration agreements with appropriate third-parties; compete successfully with other companies that are seeking to develop improved therapies for the treatment of HCV; manage expenses; manage litigation; raise the substantial additional capital needed to achieve its business objectives; and successfully execute on its business strategies. These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014, and its subsequent SEC filings.
In addition, any forward-looking statement in this press release represents Achillion's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Achillion disclaims any duty to update any forward-looking statement, except as required by applicable law.
CONTACT: Company Contact: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 firstname.lastname@example.org Investors: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 email@example.com Investors: Clayton Robertson The Trout Group, LLC Tel. (646) 378-2964 firstname.lastname@example.org
Source:Achillion Pharmaceuticals, Inc.